Unexamined Drug Epidemic–the Elephant No One Wants to See

us_troops.jpg

“Prescription drug therapy stands as one of the most significant perils to health resulting from human activity.” What’s the FDA doing to stem the tide of this preventable epidemic? Continue reading →

Treating children as young as 4 for bipolar – WSJ

Treating children as young as 4 for bipolar – WSJ Thu, 26 May 2005 A report in The Wall Street Journal should raise serious concerns about the legitimacy of psychiatric diagnosing and drug prescribing for children. The Journal reports that close to . . . Continue reading →

14 deaths force halt to drug in Canada – Hyperactivity remedy called threat to kids

http://www.nj.com/news/ledger/index.ssf?/base/news-20/1108104141208160.xml Star-Ledger 14 deaths force halt to drug in Canada Hyperactivity remedy called threat to kids Friday, February 11, 2005 BY CAROL ANN CAMPBELL Safety concerns have clouded the future of another blockbuster medication, this one a hyperactivity drug prescribed to 700,000 . . . Continue reading →

Researcher To Be Sacked After Reporting High Rates of ADHD – BMJ

Researcher To Be Sacked After Reporting High Rates of ADHD – BMJ Sun, 10 Apr 2005 The BMJ reports that Dr. Gretchen LeFever, a clinical psychologist and professor at Eastern Virginia Medical School, whose published reports (since 1995) have raised the alarm . . . Continue reading →

Infomail Archive, 2005

Infomail 2005 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Subscribe to the AHRP infomail list Dec 16: Drugs, Devices & Doctors – NYT Paul Krugman Dec 11: Scientific Fraud & Corruption on Both sides of Atlantic: Merck . . . Continue reading →

Major Drug Effectiveness Review Found "Little Evidence" that ADHD drugs are safe or effective

Major Drug Effectiveness Review Found “Little Evidence” that ADHD drugs are safe or effective Tue, 13 Sep 2005 On paper, drug manufacturers MUST demonstrate with scientific evidence that a drug is safe and effective–if they want to gain to gain FDA approval. . . . Continue reading →